文献速递肝病消化道肿瘤与早癌

质膜蛋白ADCY7的核转位增强肝细胞癌中T细胞介导的抗肿瘤免疫

Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.
PubMed 文献 · Gut · 2024-12-10

该研究通过全基因组体内CRISPR筛选发现免疫调节因子ADCY7,并利用单细胞RNA测序、流式细胞术、小鼠模型、染色质免疫沉淀和共免疫沉淀探索其在肝细胞癌免疫监视中的功能与机制。研究发现ADCY7经小窝介导的内吞和LRRC59、KPNB1辅助转位至细胞核,作为CEBPA转录辅因子诱导CCL5转录,增加CD8+ T细胞浸润抑制肿瘤进展;高ADCY7外泌体可促进瘤内CD8+ T细胞浸润并抑制肿瘤生长。

要点

  • 全基因组体内CRISPR筛选鉴定出新型免疫调节因子ADCY7。
  • ADCY7经小窝介导内吞及LRRC59、KPNB1辅助转位至细胞核。
  • 核内ADCY7作为CEBPA转录辅因子诱导CCL5转录,增加CD8+ T细胞浸润。

核心结论

  • 研究阐明了ADCY7的非经典功能与亚细胞定位,凸显其在肝细胞癌T细胞介导免疫中的关键作用及作为有前景治疗靶点的潜力。

研究设计与样本

  • 研究采用全基因组体内CRISPR筛选文库鉴定与免疫耐受相关的关键基因,并运用单细胞RNA测序、流式细胞术、肝细胞癌小鼠模型、染色质免疫沉淀和共免疫沉淀探索ADCY7在肝细胞癌免疫监视中的功能与机制。

主要发现

  • 全基因组体内CRISPR筛选鉴定出新型免疫调节因子ADCY7。
  • 跨膜蛋白ADCY7经小窝介导的内吞发生亚细胞转位,并在LRRC59和KPNB1辅助下转位至细胞核。
  • 核内ADCY7作为CEBPA的转录辅因子诱导CCL5转录,从而增加CD8+ T细胞浸润以抑制肝细胞癌进展。
  • ADCY7可以外泌体形式分泌并进入邻近肿瘤细胞促进CCL5诱导。
  • 高ADCY7水平外泌体促进瘤内CD8+ T细胞浸润并抑制肝细胞癌肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The potency of T cell-mediated responses is a determinant of immunotherapy effectiveness in treating malignancies; however, the clinical efficacy of T-cell therapies has been limited in hepatocellular carcinoma (HCC) owing to the extensive immunosuppressive microenvironment. OBJECTIVE: Here, we aimed to investigate the key genes contributing to immune escape in HCC and raise a new therapeutic strategy for remoulding the HCC microenvironment. DESIGN: The genome-wide in vivo clustered regularly interspaced short palindromic repeats (CRISPR) screen library was conducted to identify the key genes associated with immune tolerance. Single-cell RNA-seq (scRNA-seq), flow cytometry, HCC mouse models, chromatin immunoprecipitation and coimmunoprecipitation were used to explore the function and mechanism of adenylate cyclase 7 (ADCY7) in HCC immune surveillance. RESULTS: Here, a genome-wide in vivo CRISPR screen identified a novel immune modulator-ADCY7. The transmembrane protein ADCY7 undergoes subcellular translocation via caveolae-mediated endocytosis and then translocates to the nucleus with the help of leucine-rich repeat-containing protein 59 (LRRC59) and karyopherin subunit beta 1 (KPNB1). In the nucleus, it functions as a transcription cofactor of CCAAT/enhancer binding protein alpha (CEBPA) to induce CCL5 transcription, thereby increasing CD8+ T cell infiltration to restrain HCC progression. Furthermore, ADCY7 can be secreted as exosomes and enter neighbouring tumour cells to promote CCL5 induction. Exosomes with high ADCY7 levels promote intratumoural infiltration of CD8+ T cells and suppress HCC tumour growth. CONCLUSION: We delineate the unconventional function and subcellular location of ADCY7, highlighting its pivotal role in T cell-mediated immunity in HCC and its potential as a promising treatment target.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Chen J, Jiang Y, Hou M, et al. Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC. Gut. 2024. PMID: 39349007. doi:10.1136/gutjnl-2024-332902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。